Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Operating Expenses (2020 - 2025)

Maxcyte (MXCT) has disclosed Operating Expenses for 6 consecutive years, with $19.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 4.47% to $19.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $81.1 million, a 5.26% decrease, with the full-year FY2024 number at $82.7 million, down 2.5% from a year prior.
  • Operating Expenses was $19.4 million for Q3 2025 at Maxcyte, down from $21.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $22.2 million in Q1 2024 to a low of $10.7 million in Q2 2021.
  • A 5-year average of $18.1 million and a median of $19.4 million in 2025 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 60.38% in 2022, then decreased 12.96% in 2024.
  • Maxcyte's Operating Expenses stood at $13.9 million in 2021, then rose by 26.99% to $17.6 million in 2022, then rose by 25.87% to $22.2 million in 2023, then fell by 12.96% to $19.3 million in 2024, then increased by 0.36% to $19.4 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Operating Expenses are $19.4 million (Q3 2025), $21.2 million (Q2 2025), and $21.2 million (Q1 2025).